• Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit
• Concordance analysis between MMAI and 21-gene Recurrence Score test in breast cancer

SAN FRANCISCO: Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago.

Two breast cancer abstracts demonstrate the performance of Artera’s MMAI across clinically challenging settings. One study assesses prognosis and chemotherapy benefit stratification in node‑positive HR+ breast cancer, and a separate study evaluates the prognostic performance of MMAI against the 21‑gene Recurrence Score test in a retrospective node‑negative disease cohort.

“These studies expand our understanding of how Artera performs across increasingly complex breast cancer populations,” said Calvin Chao, MD, PhD, Vice President of Medical Science at Artera. “Together, they reinforce the ability of MMAI to provide more refined risk assessment in both node-negative and node-positive disease and further support treatment decision-making for clinicians and patients.”

The breast cancer data being presented at ASCO 2026 builds on recent momentum in this disease area following the U.S. Food and Drug Administration (FDA) clearance of ArteraAI Breast, a software‑as‑a‑medical‑device (SaMD) for risk stratification in early‑stage HR‑positive, HER2‑negative invasive breast cancer.

Artera will also be exhibiting at ASCO 2026 at Booth #11047, where attendees can learn more about the Artera platform.

Breast Cancer Presentations at ASCO 2026

Oral Presentation: External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814
Abstract Number: #107
Session Type and Title: Oral Session – Clinical Science Symposium
Date and Time: June 1st, Hall D1, 9:45–11:15 AM CT
Summary: This study extends prior validation of MMAI in node‑negative disease into node‑positive HR+ breast cancer, addressing the clinically challenging 1–3 node population where uncertainty about chemotherapy benefit is common.

Poster Presentation: Prognostic Performance of a Multimodal Artificial Intelligence Histopathology-Based Tool Versus the 21-Gene Recurrence Score in Early-Stage Breast Cancer
Abstract Number: #559
Session Type and Title: Poster Session – Breast Cancer – Local/Regional/Adjuvant
Date and Time: June 1st, Hall A, 1:30–4:30 PM CT
Summary: The study demonstrated strong concordance between MMAI and the 21‑gene Recurrence Score test in identifying low‑risk patients with favorable outcomes, while providing additional prognostic clarity in low and intermediate‑risk disease, using digital pathology images without additional tissue consumption.

Prostate Cancer Presentations at ASCO 2026

In addition to breast cancer, Artera will also present data in localized prostate cancer, further supporting the robustness and generalizability of its platform.

Poster Presentation: Image-Only and Multimodal AI Digital Pathology Biomarkers Demonstrate Consistent Risk Stratification Across Standard Prostate Cancer Management Strategies
Abstract Number: #5023
Session Type and Title: Poster Session – Genitourinary Cancer – Prostate, Testicular, and Penile
Date and Time: May 31st, Hall A, 9:00 AM–12:00 PM CT
Summary: Building on data previously presented at the Society of Urologic Oncology Annual Meeting 2025 and published in Reviews in Urology, this study further demonstrates that image-only and multimodal AI models derived from routine pathology can consistently stratify metastatic risk in localized prostate cancer across multiple-institutional real-world cohorts, despite differences in standard management strategies.

Poster Presentation: Assessing the Clinical and Biological Associations Between Multimodal Artificial Intelligence (MMAI) and 22-Gene Genomic Classifier (GC) in Localized Prostate Cancer (PCa)
Abstract Number: #539640
Session Type and Title: Poster Session – Genitourinary Cancer – Prostate, Testicular, and Penile
Date and Time: May 31st, Hall A, 9:00 AM–12:00 PM CT
Summary: This exploratory study compares MMAI with a 22‑gene genomic classifier in localized prostate cancer, showing that both are associated with outcomes while often assigning risk differently, building on prior validation of MMAI presented by Melvin Chua, MD, PhD, at ASTRO 2025 in an Asian patient cohort, supporting its performance across diverse populations.

About Artera

Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe.

Artera’s FDA-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in vitro diagnostic tests, supporting regulated availability in international markets.

Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.

Artera’s headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit artera.ai.

Fonte: Business Wire